Forest Laboratories, Inc. Announces Additional Settlement Agreements in BYSTOLIC® Patent Litigation

  Forest Laboratories, Inc. Announces Additional Settlement Agreements in
  BYSTOLIC® Patent Litigation

Business Wire

NEW YORK -- November 28, 2012

Forest Laboratories, Inc. (NYSE: FRX) and Forest Laboratories Holdings, Ltd.
(collectively,“Forest”) announced today that they have entered into settlement
agreements with Alkem Laboratories, Ltd. ("Alkem"), Indchemie Health
Specialties Pvt. Ltd. ("Indchemie"), and Torrent Pharmaceuticals Ltd. and
Torrent Pharma Inc. (collectively, "Torrent") in patent infringement
litigation brought by Forest in response to abbreviated new drug applications
(ANDAs) filed by Alkem, Indchemie and Torrent each seeking approval to market
generic versions of Forest’s BYSTOLIC® (nebivolol) tablets. These settlement
agreements are in addition to the previously announced Bystolic patent
infringement settlement agreement with Hetero Labs Ltd.

Specifically, under the terms of the settlement agreements and subject to
review of the settlement terms by the U.S. Federal Trade Commission, Forest
will provide licenses to each of Alkem, Indchemie and Torrent that will permit
these companies to launch their generic versions of BYSTOLIC® as of the date
that is the later of (a) three calendar months prior to the expiration of U.S.
Patent No. 6,545,040, including any extensions and/or pediatric exclusivities
or (b) the date each company receives final FDA approval of its ANDA, or
earlier in certain circumstances.

Similar patent infringement litigation brought by Forest against Amerigen
Pharmaceuticals Ltd., Glenmark Generics Inc., Watson Pharmaceuticals Inc., and
related companies and subsidiaries thereof, remains pending in a multidistrict
litigation established in the U.S. District Court for the Northern District of
Illinois.

About Forest Laboratories

Forest Laboratories, Inc. (NYSE: FRX) is a U.S.-based pharmaceutical company
with a long track record of building partnerships and developing and marketing
products that make a positive difference in people’s lives. In addition to its
well-established franchises in therapeutic areas of the central nervous and
cardiovascular systems, Forest’s current pipeline includes product candidates
in all stages of development and across a wide range of therapeutic areas. The
Company is headquartered in New York, NY. To learn more about Forest
Laboratories, visit www.FRX.com.

Except for the historical information contained herein, this release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve a number of risks and
uncertainties, including the difficulty of predicting FDA approvals, the
acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories’ Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and
any subsequent SEC filings. Forest assumes no obligation to update
forward-looking statements contained in this release to reflect new
information or future events or developments.

Contact:

Forest Laboratories, Inc.
Frank J. Murdolo, 1-212-224-6714
Vice President - Investor Relations, Forest Laboratories, Inc.
Frank.Murdolo@frx.com
 
Press spacebar to pause and continue. Press esc to stop.